Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT05640726
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Sponsor: Fujian Cancer Hospital
Conditions
Rectal Cancer
Interventions
5-fluorouracil Bevacizumab Calcium folinate Oxaliplatin PD-1 SCRT
Updated 3 times since 2023 Last updated: Dec 6, 2022 Started: May 1, 2023 Primary completion: May 1, 2024 Completion: May 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Rectal Cancer and is currently actively recruiting participants. Fujian Cancer Hospital leads this study, which shows 3 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
3 versions recorded-
Sep 2024 — Present [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Fujian Cancer Hospital
Data source: Fujian Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.